| Gemcitabine for recurrent ovarian cancer-a systematic review and meta-analysis T Berg, TJ Nøttrup, H Roed Gynecologic oncology 155 (3), 530-537, 2019 | 31 | 2019 |
| Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish … T Berg, MB Jensen, EH Jakobsen, S Al-Rawi, J Kenholm, M Andersson The Breast 54, 242-247, 2020 | 19 | 2020 |
| Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2− metastatic breast cancer KB Kristensen, IMN Thomsen, T Berg, AR Kodahl, AB Jensen Breast Cancer Research and Treatment 188, 799-809, 2021 | 11 | 2021 |
| Dual HER2 blockade in the first-line treatment of metastatic breast cancer-A retrospective population-based observational study in Danish patients T Christensen, T Berg, LB Nielsen, M Andersson, MB Jensen, A Knoop The Breast 51, 34-39, 2020 | 11 | 2020 |
| First-line treatment of HER2-positive metastatic breast cancer with dual blockade including biosimilar trastuzumab (SB3): population-based real-world data from the DBCG A Celik, T Berg, LB Nielsen, MB Jensen, B Ejlertsen, A Knoop, ... Breast Cancer: Basic and Clinical Research 16, 11782234221086992, 2022 | 8 | 2022 |
| Treatment and outcomes of a Danish ovarian cancer population T Berg, TJ Nøttrup, UBS Peen, H Roed IIB 8, 6, 2020 | 5 | 2020 |
| Identifying recurrent breast cancer patients in national health registries using machine learning AD Lauritzen, T Berg, MB Jensen, M Lillholm, A Knoop Acta Oncologica 62 (4), 350-357, 2023 | 2 | 2023 |
| Registry data and conditioning therapy for allogeneic hematopoietic cell transplant and lymphoma T Berg, HS Mian, RM Meyer JAMA oncology 6 (7), 989-991, 2020 | 2 | 2020 |
| Treating brain metastases in metastatic breast cancer: outcomes after stereotactic radiosurgery examined in a retrospective, single-center cohort analysis JF Depner, T Berg, B Ejlertsen, LW Andreasen, S Møller, MV Maraldo Acta Oncologica 62 (11), 1502-1510, 2023 | 1 | 2023 |
| Real-World Survival and Treatment Regimens Across First-to Third-Line Treatment for Advanced Triple-Negative Breast Cancer A Celik, T Berg, MB Jensen, E Jakobsen, HM Nielsen, I Kümler, V Glavicic, ... Breast Cancer: Basic and Clinical Research 17, 11782234231203292, 2023 | 1 | 2023 |
| Atezolizumab and nab-paclitaxel for advanced breast cancer in Danish real-world patients R Garly, A Knoop, MB Jensen, T Berg, HM Nielsen, I Kümler Danish Medical Journal 70 (9), A01230034-A01230034, 2023 | 1 | 2023 |
| A retrospective, non-interventional study of breast cancer patients diagnosed with ER+/HER2 negative, locally advanced or metastatic breast cancer treated with palbociclib in … R Garly, T Berg, MB Jensen, A Knoop, L Volmer, V Glavicic, H Khan, ... Acta Oncologica 62 (3), 290-297, 2023 | 1 | 2023 |
| Molecular subtyping improves breast cancer diagnosis in the Copenhagen Breast Cancer Genomics Study T Berg, MB Jensen, A Celik, ML Talman, MA Misiakou, AS Knoop, ... JCI insight 9 (7), 2024 | | 2024 |
| Medicinsk behandling af fremskreden brystkræft T Berg, AS Knop, EH Jakobsen Ugeskrift for Læger 186 (6), V02230071, 2024 | | 2024 |
| Development and Methodological Validation of a Modified Staging System for de Novo Metastatic Breast Cancer T Berg, MB Jensen, M Rossing, T Bechmann, F Donskov, AS Knoop, ... JAMA network open 7 (3), e242174-e242174, 2024 | | 2024 |
| Medical treatment of advanced breast cancer. T Berg, AS Knop, EH Jakobsen Ugeskrift for Laeger 186 (12), V02230071-V02230071, 2024 | | 2024 |
| Prognostic Value of Pre-treatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer HH Andersen, SE Bojesen, JS Johansen, B Ejlertsen, T Berg, M Tuxen, ... Cancer Epidemiology, Biomarkers & Prevention, 2024 | | 2024 |
| High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients K Nielsen, M Sode, MB Jensen, T Berg, A Knoop, B Ejlertsen, ... Breast Cancer Research 25 (1), 139, 2023 | | 2023 |
| 391P Detrimental effect on overall survival of CDK4/6 inhibitor dose reduction if immortal time bias is considered A Bjerrum, AF Henriksen, AS Knop, T Berg, IEV Tuxen, UN Lassen, ... Annals of Oncology 34, S344-S345, 2023 | | 2023 |
| Real-world survival of Danish patients with HER2-positive metastatic breast cancer D Artzi, T Berg, A Celik, I Kümler, J Kenholm, S Al-Rawi, MB Jensen, ... Acta Oncologica 62 (6), 601-607, 2023 | | 2023 |
